Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye.
Current Team (8)Update
Funding Rounds (2) - $114.5MUpdate
Board Members and Advisors (2)Update
Healthcare investment firm
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since...
DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device...
Spray Venture Partners focuses exclusively on contributing capital and expertise to emerging...
Venture Capital Firm
General Catalyst Partners is a venture capital firm that makes early-stage and growth equity...
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads...
5151 McCrimmon Parkway
Morrisville, NC 27560